Takeda Pharmaceutical Company （TAK） 2022年度综合报告「NYSE」.pdf

1、2022 Annual Integrated ReportFiscal Year Ended March 31,2022Contents03 CEO Letter to Stakeholders05 Message from the External Director,Chair of the Board Meeting06 Dialogue with CGCASO1 andCFO18 Values-Based Governance64 Legal Disclaimers66 Appendix68 Reconciliations07 About this Report08 FY2021 Hig

2、hlights09 Our Business Environment12 About Takeda16 Spotlight on Hikari Plant40COMMITMENT TO PEOPLE28COMMITMENT TO PATIENT46COMMITMENT TO PLANET56FINANCIAL PERFORMANCE61GLOBAL CSR1 CGCASO=Chief Global Corporate Affairs&Sustainability OfficerTAKEDA 2022 ANNUAL INTEGRATED REPORT2P A T I E N TP E O P L

3、 EP L A N E TF I N A N C I A L SG L O B A L C S RG O V E R N A N C EI N T R O D U C T I O NDear Stakeholders,Takeda has existed for more than 240 years,yet we arereminded each day of the critical importance ofour work,and we are fueled by the impact we make in our mission to transform lives.We often

4、 talk about the importance of our core values of Takeda-ism(Integrity,Fairness,Honesty and Perseverance)brought to life through actions based on patient,trust,reputation and business,in that order.These values guide everything we do and are fundamental to who weare as a company.Our purpose,as a core

5、 foundation of our global growth strategy,will help us create value for decades to come.Transforming the lives of patientsThe work we do transforms lives,helping patients withlimited or no treatment options in our therapeutic and business areas of oncology,rare genetics and hematology,neuroscience,g

6、astroenterology,plasma-derived therapies(PDT)and vaccines.Our R&D pipeline is a clear demonstration of how we are working to deliver unique value to patients.We have a robust pipeline of medicines that all have the potential to transform the treatment landscape.Unleashing the power of data and techn